The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 381-385

  Kovarik, John M ^a   Huang, Hsun Lun A ^a   Slade, Alan ^a   Sfikas, Nikos ^a   Chandler, Patricia A ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Covance ^*  (United States)

Author keywords

Drug interactions; Immunomodulators; Ketoconazole; Protein kinase C; Sotrastaurin

Indexed keywords

CYTOCHROME P450 3A4; KETOCONAZOLE; N DESMETHYL SOTRASTAURIN; SOTRASTAURIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; MALE; PYRROLES; QUINAZOLINES; YOUNG ADULT;

EID: 69949188055     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03457.x     Document Type: Article

References (9)

1. Skvara H, Dawid M, Kleyn CE, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CEM, Stingl G, Jung T. Potential therapeutic option for psoriasis with aeb071, a novel protein kinase c inhibitor. J Clin Invest 2008 118 : 3151 3159.
2. Bjornsson TD, Callaghan JT, Einholf HJ. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003 43 : 443 469.
3. United States Food and Drug Administration. Draft guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. 2006. Available at http://www.fda.gov/drugs/ guidancecomplianceregulatoryinformation/guidances (last accessed 17 June 2009).
4. Choc MG, Mueller EA, Robinson WT, Kuhmle A, Smith HT, Charnick SB. Relative bioavailability of Neoral ver s us Sandimmun in the presence of a P450IIIA and P-glycoprotein inhibitor. Transplant Proc 1998 30 : 1664 1665.
5. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Herbert MF. Tacrolimus oral bioavailability doubles with co-administration of ketoconazole. Clin Pharmacol Ther 1997 62 : 41 9.
6. Floren LC, Christians U, Zimmerman JJ, Neefe L, Schorer R, Rushworth D, Harper D, Renz J, Benet LZ. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole (abstract). Clin Pharmacol Ther 1999 65 : 159.
7. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005 45 : 514 518.
8. el-Agroudy AE, Sobh AE, Hamdy MA, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation 2004 77 : 1371 1376.
9. Tuteja S, Alloway RR, Johnson JA, Gaber O. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001 71 : 1303 1307.